share_log

CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

CRISPR Therapeutics | 8-K: CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

CRISPR Therapeutics | 8-K:CRISPR Therapeutics提供最新業務並公佈2024年第三季度財務業績
美股SEC公告 ·  2024/11/05 22:06

Moomoo AI 已提取核心訊息

On November 5, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the third quarter ending September 30, 2024, along with key business highlights. The company reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities. Research and development expenses decreased compared to the previous year, and the company experienced a net loss of $85.9 million for the quarter, an improvement over the prior year's net loss. CRISPR Therapeutics also provided updates on its product pipeline, including the regulatory approval of CASGEVY for SCD and TDT in Switzerland and Canada, the activation of 45 treatment centers globally, and the collection of cells from approximately 40 patients. The company highlighted ongoing clinical trials for its next-generation CAR T...Show More
On November 5, 2024, CRISPR Therapeutics AG, a biopharmaceutical company, announced its financial results for the third quarter ending September 30, 2024, along with key business highlights. The company reported a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and marketable securities. Research and development expenses decreased compared to the previous year, and the company experienced a net loss of $85.9 million for the quarter, an improvement over the prior year's net loss. CRISPR Therapeutics also provided updates on its product pipeline, including the regulatory approval of CASGEVY for SCD and TDT in Switzerland and Canada, the activation of 45 treatment centers globally, and the collection of cells from approximately 40 patients. The company highlighted ongoing clinical trials for its next-generation CAR T product candidates, CTX112 and CTX131, and its in vivo gene editing product candidates, CTX310 and CTX320. Additionally, CRISPR Therapeutics is advancing CTX211, a treatment for Type 1 Diabetes, and expects to initiate clinical trials for CTX340 and CTX450 in the second half of 2025. The company's collaboration with Vertex Pharmaceuticals continues, with Vertex leading the global development, manufacturing, and commercialization of CASGEVY.
2024年11月5日,crispr therapeutics AG,一家生物製藥公司,宣佈截至2024年9月30日第三季度的財務業績,以及主要業務亮點。該公司報告稱資產負債表強勁,現金、現金等價物和市場證券約爲19億美元。研發費用與去年相比有所下降,該公司季度淨損失達到8590萬美元,較去年同期淨損失有所改善。CRISPR Therapeutics還介紹了其產品管道的最新進展,包括CASGEVY在瑞士和加拿大獲得SCD和TDt的監管批准,全球擁有45個治療中心並從約40名患者中收集細胞。該公司強調了其CAR t下一代產品候選藥CTX112和CTX131以及其體內基因編輯產品候選藥CTX310和...展開全部
2024年11月5日,crispr therapeutics AG,一家生物製藥公司,宣佈截至2024年9月30日第三季度的財務業績,以及主要業務亮點。該公司報告稱資產負債表強勁,現金、現金等價物和市場證券約爲19億美元。研發費用與去年相比有所下降,該公司季度淨損失達到8590萬美元,較去年同期淨損失有所改善。CRISPR Therapeutics還介紹了其產品管道的最新進展,包括CASGEVY在瑞士和加拿大獲得SCD和TDt的監管批准,全球擁有45個治療中心並從約40名患者中收集細胞。該公司強調了其CAR t下一代產品候選藥CTX112和CTX131以及其體內基因編輯產品候選藥CTX310和CTX320正在進行的臨床試驗。此外,CRISPR Therapeutics正在推進用於1型糖尿病治療的CTX211,並計劃在2025年下半年啓動CTX340和CTX450的臨床試驗。該公司與福泰製藥的合作繼續進行,福泰製藥領導CASGEVY的全球發展、製造和商業化。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息